Here is what they contain, side by side with the doses that clinical studies actually used: The dosing gap is the core problem
Can I use phentermine and GLP-1 together
Results In the GLP-1 RA vs SGLT-2 inhibitor cohort (2014-2022) we identified 83,464 new users of GLP-1 RAs and 78,366 new users of SGLT-2 inhibitors
Muscle pain from rapid lean mass loss and protein deficiency tends to develop more slowly, typically becoming noticeable in weeks three to six of therapy
I'm not, you know, I'm 90%, 80% of the time I'm doing the right things the right way, I think, although I'm now going to improve on them with this new knowledge
The results of the SURPASS-CVOT will define the impact of tirzepatide on cardiovascular disease